TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00777894

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~1. (3 patients) 27 x 2 Gy = 54 Gy~2. (3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~3. (3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~4. (5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~5. (5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed.
Study: NCT00790699

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-PORT
Description: The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard injections
Description: The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
Study: NCT01100151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDC-1036 (ALKS 37)
Description: Capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral administration
Study: NCT02357966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 514G3 (2 mg/kg) plus standard IV antibiotic treatment
Description: True Human Monoclonal Antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 514G3 (10 mg/kg) plus standard IV antibiotic treatment
Description: True Human Monoclonal Antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 514G3 (40 mg/kg) plus standard IV antibiotic treatment
Description: True Human Monoclonal Antibody

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo plus standard IV antibiotic treatment
Description: Sterile isotonic formulation buffered at pH 6.2 - 6.5 plus standard IV antibiotic treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II
Description: A single dose of 514G3 plus standard IV antibiotic therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo plus standard IV antibiotic treatment: Phase II
Description: A single dose of placebo plus standard IV antibiotic therapy
Study: NCT00441142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: During the 'Induction' phase: 75/mg/m2/day temozolomide will be given orally daily for 6 weeks (42 days) during radiation therapy, beginning either the night before or on the first day of the first fraction of radiation, including weekends and holidays. This is followed by a 4-6 week break.~During the 'Maintenance' phase: The first post-radiation temozolomide cycle will be administered at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle. If 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given. This is given for 12 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: During the 'Induction' phase: 75/mg/m2/day temozolomide will be given orally daily for 6 weeks (42 days) during radiation therapy, beginning either the night before or on the first day of the first fraction of radiation, including weekends and holidays. This is followed by a 4-6 week break.~During the 'Maintenance' phase: The first post-radiation temozolomide cycle will be administered at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle. If 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given. This is given for 12 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiotherapy must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Radiotherapy must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy.
Study: NCT03347409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changes in preoperative care
Description: Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changes in intraoperative care
Description: Blended anesthesia is mostly carried out using Total Intra Venous Anesthesia (TIVA) with loco regional analgesia, in particular Thoracic Epidural Anesthesia (TEA) in open surgery and spinal morphine or Transversus Abdominis Plane (TAP) block or quadratus lumborum block for laparoscopic surgical approach, associated to NSAIDs or acetaminophen; control of deep neuromuscular blocking with Train-of-four (TOF) stimulation avoiding residual paralysis. Multimodal prevention of PONV (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.
Study: NCT01060449

Intervention type: OTHER
Group type: OTHER
Intervention: LV stimulus intensity
Description: The voltage and pulse duration used for programmed LV pacing~Arm 1: LV lead low output Arm 2: LV lead high output

Intervention type: OTHER
Group type: OTHER
Intervention: LV stimulus intensity
Description: The voltage and pulse duration used for programmed LV pacing~Arm 1: LV lead low output Arm 2: LV lead high output
Study: NCT03679858

Intervention type: OTHER
Intervention: Platelet function test
Description: Ex vivo platelet aggregation analysis by Multiplate aggregometer

Intervention type: OTHER
Intervention: Platelet function test
Description: Ex vivo platelet aggregation analysis by Multiplate aggregometer
Study: NCT01753856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Administered orally
Study: NCT03171415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZL-012
Description: Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject receive a single-time injection. Multiple injections of the Placebo are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
Study: NCT05993468

Intervention type: OTHER
Intervention: TMC Treatment Approach
Description: The TMC approach consists of 16 weekly group sessions, each lasting 2 hours. The first 10 sessions focus mainly on building mindfulness capacities, and the last 6 sessions on developing compassion toward self and others. Between sessions, participants are encouraged to do exercises with the support of audio files. The approach was developed with a transdiagnostic perspective, including clients with a variety of trauma-related symptoms.

Intervention type: OTHER
Intervention: TMC Treatment Approach
Description: The TMC approach consists of 16 weekly group sessions, each lasting 2 hours. The first 10 sessions focus mainly on building mindfulness capacities, and the last 6 sessions on developing compassion toward self and others. Between sessions, participants are encouraged to do exercises with the support of audio files. The approach was developed with a transdiagnostic perspective, including clients with a variety of trauma-related symptoms.
Study: NCT02888444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Two 0.5mg tablets taken twice daily

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioural support
Description: Consisting of the study-specific doctor delivering relapse prevention orientated behavioural support at the time of consultation, plus six 10-15 minute calls over the 12 weeks delivered by a research assistant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioural support
Description: Consisting of the study-specific doctor delivering relapse prevention orientated behavioural support at the time of consultation, plus six 10-15 minute calls over the 12 weeks delivered by a research assistant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two 0.5mg tablets taken twice daily
Study: NCT03694821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine Injection
Description: One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Acetate Injection
Description: One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylan G-F 20
Description: One knee injection of Hylan G-F 20 (Synvisc-One)
Study: NCT03347409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changes in postoperative care
Description: Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV. According to the type of surgery TEA, TAP block , quadratus lumborum block or IT morphine is preferred. Patient is proposed to start drinking clear fluid 4 hours after surgery and to start eating the evening of the surgery, with the introduction of a normal free diet within 24 hours after surgery. It is proposed to chew gum three times daily for at least 15 minutes and eventually to use laxatives to promote a faster bowel function. Early mobilization is started from the evening of surgery.
Study: NCT04203966

Intervention type: DIAGNOSTIC_TEST
Intervention: 12-item General Health Questionnaire (GHQ-12)
Description: Structured validated screening tools to assess for the presence of CMDs, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
Study: NCT06798051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxithromycin tablets 150mg
Description: Oral roxithromycin tablets，150mg Once every seven days，One cycle T drug, two cycles R drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxithromycin tablets 150mg
Description: Oral roxithromycin tablets，150mg Once every seven days，One cycle T drug, two cycles R drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxithromycin tablets 150mg
Description: Oral roxithromycin tablets，150mg Once every seven days，One cycle T drug, two cycles R drug
Study: NCT04358120

Intervention type: DEVICE
Group type: OTHER
Intervention: Hyaluronic Acid Combined With Chondroitin Sulfate
Description: Subjects' participation in the study will last 26 weeks. The study includes 7 visits that consist of a Screening visit, three treatment visits and three follow-up visits.~Eligible subjects will undergo a Baseline visit (V1 at week 0) during which, after the confirmation of eligibility, assessments and ultrasound evaluation, the study subjects will be treated with the 1st injection of 2%Hyaluronic Acid and 2% chondroitin sulfate Subsequent treatments will be administered at weekly intervals during Visit 2 (V2 at week 1) and Visit 3 (Visit 3 at week 2) after the effectiveness assessments.~Study subjects will return for Follow-up visits 1 month (Visit 4 at week 6), 3 months (Visit 5 at week 14) and 6 months (Visit 6 at week 26) after the last injection
Study: NCT01217840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drisdol (Ergocalciferol) Vitamin D2
Description: Ergocalciferol 150,000 IU every 12 weeks for total of 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill - 3 pills every 12 weeks for total of 24 weeks
Study: NCT04203966

Intervention type: DIAGNOSTIC_TEST
Intervention: WHO AUDIT (World Health Organization- Alcohol Use Disorders Inventory Tool)
Description: Structured validated screening tools to assess for the presence of alcohol use disorders, administered to participants who have consented to take part in the study by completing responses either via survey monkey, or if they prefer through paper questionnaires posted to them
Study: NCT04276506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music group
Description: to reduce anxiety, some selected music pieces will have patients listened by headset.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: information group
Description: A visual information booklet which is prepared by the researchers will be used
Study: NCT01171638

Intervention type: DEVICE
Intervention: Near infrared spectroscopy (NIRS)
Description: Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.

Intervention type: DEVICE
Intervention: Near infrared spectroscopy (NIRS)
Description: Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
Study: NCT05901532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Szechwan Lovage Rhizome, Biod Magnolia Bud, Taiwan Angelica Root, Wild Mint Herb, Baikal Skullcap Root, and Borneol
Description: The bilateral nasal cavity was irrigated with a plastic bottle containing 1 gram of Szechwan Lovage Rhizome, 1 gram of Biod Magnolia Bud, 0.5 gram of Taiwan Angelica Root, 0.5 gram of Wild Mint Herb, 1.5 gram of Baikal Skullcap Root, and 0.5 gram of Borneol dissolved in 240 ml of warm normal saline once a day for 2 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: edible caramel
Description: The bilateral nasal cavity was irrigated with a plastic bottle containing edible caramel dissolved in 240 ml of warm normal saline once a day for 2 months.
Study: NCT01115140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin plus placebo
Description: metformin 850 mg cp, 2 cps daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin plus folic acid
Description: metformin 850 mg cp, 2 cps daily plus folic acid 0.4 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo plus folic acid
Description: Placebo 1 cp daily plus folic acid 0.4 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo alone
Description: placebo cp, 2 cps daily
Study: NCT01215747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KIACTA (eprodisate disodium)
Description: Orally 1 to 3 capsules (Kiacta 400 mg) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally 1 to 3 capsules (placebo) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases:
Study: NCT03912909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin Oral Tablet [Jardiance]
Description: Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin Oral Tablet [Jardiance]
Description: Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
Study: NCT01894399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM61713
Description: Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM61713
Description: Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM61713
Description: Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM61713
Description: Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM61713
Description: Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian
Study: NCT03407079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Sucralose is an organochlorine and is approximately 600 times sweeter than sucrose. Participants will receive sucralose (approximately 4mg/kg/day) or placebo by mouth in a capsule for 28 days. This dose corresponds to the amount of sucralose contained in approximately 3 or 4 twelve ounce cans of commercially-available diet soda for a 70 kg adult.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be taken orally for 28 days
Study: NCT01894399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM61713
Description: Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM61713
Description: Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian